Clearmind Medicine Inc Dossier - Source-backed chat

Clearmind Medicine Inc

CMNDNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)-0.43

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.72Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.4M

Enterprise Value −$6.8M

Shares Outstanding 3.4M diluted

Next Earnings Date20 Jan 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Clearmind Medicine Inc. is a clinical-stage neuroplastogens pharmaceutical biotech company focused on developing non-hallucinogenic, second-generation, psychedelic-derived therapeutics to address major under-treated health problems, primarily Alcohol Use Disorder (AUD). The company's lead candidate, CMND-100 (utilizing MEAI), has shown positive progress by completing Part A dosing of its Phase I/II clinical trial with a strong safety profile. However, as a pre-revenue biotech, Clearmind faces substantial going concern risks, recurring operating losses, and heavy reliance on dilutive equity financings. While its intellectual property portfolio is robust, the high clinical execution risk and short cash runway warrant a cautious 'Hold' recommendation until clear efficacy data or non-dilutive strategic partnerships emerge.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.2520%

The bear case materializes if CMND-100 encounters safety issues or fails to show clinical efficacy in upcoming trial phases, effectively halting its development. Under this scenario, Clearmind's limited cash runway would force highly dilutive equity offerings or lead to insolvency, potentially resulting in a delisting from Nasdaq and a complete loss of investor capital.

Base CaseCentral scenario

$3.2055%

The base case assumes Clearmind continues to steadily advance its Phase I/II trial for CMND-100, maintaining its Nasdaq listing through tactical capital raises. Efficacy data will take time to mature, and the company will remain pre-revenue with ongoing operating losses. Valuation will likely remain constrained by the constant threat of dilution and the high failure rate typical of early-stage CNS therapeutics.

Bull CaseUpside scenario

$6.5025%

The bull case is driven by successful clinical advancement of CMND-100, demonstrating strong efficacy in reducing alcohol consumption during Phase II trials. This would validate the 'enough switch' mechanism of MEAI and potentially attract a major pharmaceutical partner, leading to a lucrative licensing deal. Additionally, expansion of the pipeline into metabolic disorders (obesity/weight loss) in combination with GLP-1 therapies could open up massive addressable markets.

Scenarios reflect our research view at the research date.

Key Investment Merits

Successful completion of Part A dosing for the Phase I/II clinical trial of lead candidate CMND-100, demonstrating a strong safety profile.
Robust intellectual property portfolio consisting of 19 patent families and 31 granted patents globally.
Targeting highly underserved markets with massive economic burdens, such as Alcohol Use Disorder (AUD) and binge behaviors.
Strategic collaborations with prestigious institutions like Johns Hopkins University and Yale School of Medicine for clinical trials.

Key Investment Risks

Substantial going concern risk with an accumulated deficit of $33.8M as of April 30, 2026, and recurring operating losses.
High risk of shareholder dilution due to frequent equity offerings and outstanding warrant liabilities used to fund operations.
Early-stage clinical pipeline with no approved products and no current source of revenue.
Strict regulatory hurdles and high clinical development failure rates inherent to central nervous system (CNS) and psychedelic-derived drugs.

Thesis Invalidation Triggers

Failure of CMND-100 to demonstrate statistical significance or efficacy in Phase II clinical trials.
Inability to secure additional financing, leading to a breach of going concern covenants or bankruptcy.
Severe adverse safety events reported in clinical trials, leading to an FDA clinical hold.
Delisting from the Nasdaq Capital Market due to failure to meet minimum bid price or equity requirements.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.